Teva Completes Facilities Purchase in Pennsylvania for North America Research & Development Campus

Teva Pharmaceuticals USA, Inc. today announced that the company has completed the purchase of three buildings on Brandywine Parkway in West Chester, Pa., which, together with three other buildings Teva owns in the same corporate park, firmly establishes a North America Research & Development (R&D) campus. Focused primarily on biologics, a core R&D platform on which the company continues to build for future growth, the R&D campus further augments the company’s significant U.S. presence.

“With our late-stage biologics R&D development teams co-located on a single campus, the company has created a one-stop shop for biologics development and clinical manufacturing,” says Mehran Yazdanian, Senior Director, Specialty R&D Scientific Strategy & Operations, Global R&D and Site Head. “From cell bank to syringe, our West Chester R&D campus is home to many of the North American-based R&D teams and processes that will bring more biologics treatment options to patients, and support Teva’s global mission to improve lives.”

Teva purchased 400, 500 and 600 Brandywine Parkway, which the company had been leasing since 2007 and, along with 100, 200 and 300 Brandywine Parkway, now owns approximately 314,000 square feet in West Chester dedicated to feeding Teva’s future pipeline and portfolio.

Representing a significant investment over the last 12 years in capital improvements, infrastructure and now the purchase of these three buildings, Teva’s West Chester R&D campus houses clinical development and manufacturing processes for highly complex biologic medicines developed by Teva. The campus also includes laboratories where advanced preclinical and clinical testing is conducted to ensure the safety and effectiveness of new drugs. Approximately 650 employees will be based at Teva in West Chester by the end of 2019, including teams involved in combination product and device R&D, regulatory affairs, medical affairs, and support functions.

Teva employs approximately 7,000 employees in multiple locations in the US in manufacturing, commercial, R&D and administrative functions.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at

PR Contacts
United States
Grace Ann Arnold (201) 739-2064

Yonatan Beker 972 (54) 888-5898

Share this article: